CBAI sees record day after CEO's interview with BioMedReports Print E-mail
By Staff and Wire Reports   
Wednesday, 06 January 2010 07:20

Cord Blood America (OTC:CBAI), the micro-cap penny stock with an upcoming news event/milestone saw a high of $.015 before closing up nearly 29% on Tuesday.

Matthew L. Schissler, the CEO of the company told BioMedReports that CBAI is not only opening their new state of the art lab in Las Vegas later this month, but he also revealed that the company is in strong growth and acquisition mode.

"We always try to focus on three core goals and in 2010 we are opening our new state of the art laboratory," explained Schissler. "One of those three core goals is the diversification of revenue streams.  Not only will we have our own organic growth engine, by processing and storing for our own company, but we recently entered into a letter of agreement to process and store for another very successful stem cell company. That’s going to be the flavor for 2010 and onward- diversification of revenue streams by using our new facility to its full capacity. The other goal is continued growth- like we saw mention of when we announced  in late 2009 when we signed an agreement with a national labor association, Blue Cross and Blue Shield Association. That’s how we’ll grow some more, through the insurance companies. And finally, we’re going to be very focused on acquisitions. In fact, I’ll tell  you that in 2010 we have a voracious appetite for acquisitions.  With the economy the way it is, a lot of stem cell companies are struggling and we’ve been very fortunate to have our company go in the right direction by reducing debt and raising capital. We feel it’s a very good time for us to make some acquisitions and so we’re going to be very focused on that this year."

If you're still holding shares of the company, you may want to take a look at the technical analysis video below for some guidance on trading the stock.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus